NCT05352672: An ongoing trial by Regeneron Pharmaceuticals
This trial is ongoing. It must report results 10 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05352672 |
|---|---|
| Title | A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 14, 2022 |
| Completion date | March 12, 2026 |
| Required reporting date | March 12, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 29, 2026 |
| Days late | None |